Search
-
Annual Report 2024
Media
https://www.gsk.com/media/11850/annual-report-2024.pdf
First published: 27 February 2025
-
2024 Annual Report on Form 20-F
Media
https://www.gsk.com/media/11872/2024-annual-report-on-form-20-f.pdf
First published: 03 March 2025
-
Emma Walmsley Key Priorities
Media
https://www.gsk.com/media/8161/emma-walmsley-key-priorities.pdf
First published: 06 June 2022
-
FY 2024 results slides
Media
https://www.gsk.com/media/11774/fy-2024-results-slides.pdf
First published: 05 February 2025
-
Responsible Business Performance Report 2024
Media
https://www.gsk.com/media/11863/responsible-business-performance-report-2024.pdf
First published: 27 February 2025
-
20 F 2020
Media
https://www.gsk.com/media/7971/20-f-2020.pdf
First published: 01 June 2022
-
Financial Statements 2024
Media
https://www.gsk.com/media/11854/financial-statements-2024.pdf
First published: 27 February 2025
-
Governance And Remuneration Report 2024
Media
https://www.gsk.com/media/11855/governance-and-remuneration-report-2024.pdf
First published: 27 February 2025
-
GSK and Intercell form strategic alliance to develop and commercialise innovative needle-free patch-based vaccines
Media
GlaxoSmithKline Biologicals SA (GSK) and Intercell today announced an agreement to form a strategic alliance to accelerate the development.
https://www.gsk.com/en-gb/media/press-releases/gsk-and-intercell-form-strategic-alliance-to-develop-and-commercialise-innovative-needle-free-patch-based-vaccines/
First published: 10 December 2009
-
GSK and CureVac to restructure collaboration into new licensing agreement
Media
GSK acquires full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19.
https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-restructure-collaboration-into-new-licensing-agreement/
First published: 03 July 2024
